Anchor Therapeutics

The company's pharmaceutical platform includes the development of Pepducin lipopeptide candidates and molecules targeting the intracellular domains of G protein-coupled receptors (GPCRs) to allosterically modulate GPCR signaling, providing healthcare professionals with new therapeutic options for regenerative medicine, diabetes, inflammation, and cancer.